We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Jefferies cites weight-loss drugs as it downgrades Greggs; shares slide

Mon 09 February 2026 07:13 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Greggs shares slid on Monday after Jefferies downgraded the stock to 'hold' from 'buy' and slashed the price target to 1,610p from 2,500p as it said weight-loss jabs could dent demand for the bakery chain's products.

Jefferies noted that Greggs has faced a prolonged slowdown, with like-for-like sales weakening steadily since mid2024 and volumes turning consistently negative.

"While management referenced softer consumer spending and unfavourable weather, these explanations do not, in our view, account for the persistence or depth of the trend," it said. "Q4 offered some stabilisation but fell short of expectations, with negative volumes continuing, a slowing twoyear stack, and FY26 guidance cut circa 10% below consensus."

Jefferies argued that Greggs could be facing a more structural issue.

"While investor concerns have typically focused on pricing and cannibalisation, we are increasingly of the view that the rapid uptake of GLP1 weightloss drugs is impacting Greggs," it said.

Jefferies noted that GLP-1 user numbers have risen sharply, now touching an estimated 7% of UK adults, with consumption patterns changing meaningfully.

"And the categories most affected are savoury, salty, fatty, and highcalorie foods," it pointed out.

"While the typical GLP1 demographic may only partially overlap with Greggs' customer base, those affected are likely to be higherBMI, higherfrequency consumers - precisely the customers most valuable to Greggs."

Reflecting these dynamics, Jefferies lowered its mediumterm assumptions. It now models LFL growth of 2.5%, down from 4.5%, the main swing factor being a continuation of negative volumes resulting from the enduring impact of weight-loss drugs.

Nevertheless, Jefferies said Greggs remains a highquality operator with strong brand equity, attractive return on invested capital, robust cash generation and "a stillcompelling longterm rollout opportunity".

It said weather comps will ease in 2026, cyclical pressures should fade, and store expansion continues to underpin revenue.

At 1020 GMT, the shares were down 4.9% at 1,598.42p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More stockbroker tips from ShareCast

    Latest economy and stock market articles